Abstract
IntroductionThis is a presentation of the FEP of a 23 y.o. patient. The patient had a Duration of Untreated Psychosis (DUP) of 6 months and Duration of Untreated Illness (DUI) of six years. The therapeutic response and the adverse effects of Paliperidone are being described.ObjectivesTo investigate the tolerance of Paliperidone in a patient with FEP.MethodsThe patient was assessed regularly by the psychiatric team consisting of a CT doctor and one General Adult Consultant. Appropriate psychological assessments and investigations took place.ResultsUpon admission the patient appeared guarded. She also presented with weight loss and dehydration. Initial PANSS score was 173, positive subscale 41. The patient was initially treated with monotherapy 6mg of Paliperidone. However, the heart rate was around 100 bpm culminating as high as 156 bpm. The ECG indicated sinus tachycardia. The patient presented with serious EPSs and diarrhea. Simpson-Angus Scale score 10. Metoprolol 25mg was prescribed twice a day. The clinical team proceeded in cross titration replacing Paliperidone with Olanzapine. A brain CT scan was also performed, unremarkable. After 10 days of therapy the PANSS score reduced to 102, positive subscale 21.ConclusionsInitial sinus tachycardia is a common adverse effect of Paliperidone. However in this case the tachycardia was refractory in time even after the 7th day, making an alternative SGA trial necessary.DisclosureNo significant relationships.
Highlights
ObjectivesResearch progress of metabonomics of blood endogenous small molecules in depression Methods: Metabonomics is a newly developed discipline after genomics and proteomics, and is an important part of system biology
This is a presentation of the first episode of psychosis (FEP) of a 23 y.o. patient
At present, there are many studies on the metabonomics of endogenous small molecules in MDD blood, which provides the possibility for further screening of MDD related biomarkers
Summary
Research progress of metabonomics of blood endogenous small molecules in depression Methods: Metabonomics is a newly developed discipline after genomics and proteomics, and is an important part of system biology. Metabonomics provides a new approach to explore the etiology, mechanism, prognosis and screening potential biomarkers of MDD. The changes of metabolites in blood can represent the changes of metabolites in other body fluids. This sample is easy to obtain and has less trauma, so it is the most common biological sample in clinical detection. Results: At present, there are many studies on the metabonomics of endogenous small molecules in MDD blood, which provides the possibility for further screening of MDD related biomarkers.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
